Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy

Abstract

Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule, member of the immunoglobulin gene superfamily that seems to participate in the evolution of the metastatic process. We investigated the significance of baseline soluble ICAM-1 levels on the outcome of patients with small-cell lung cancer and whether soluble ICAM-1 is a predictive marker for objective response during and after chemotherapy in patients with small-cell lung cancer. Fifty patients with recently diagnosed small-cell lung cancer, as well as 27 healthy smokers, were enrolled. Blood samples were collected at the time of diagnosis, during and at the end of chemotherapy. Data were correlated with the characteristics of the patients and survival as well as with ICAM-1 predictive role for objective response. Statistical significant values of baseline soluble ICAM between patients and controls (p < 0.001) were observed. Multivariate analysis revealed an elevated risk of death of 9 % in the first year after diagnosis for every 10 units of increased soluble ICAM-1 at the baseline (p = 0.046). Performance status and disease stage were also independent prognostic factors. Patients with extensive disease who achieved an objective response during chemotherapy showed a significant decrease (25.8 %) in their soluble ICAM-1 levels compared with baseline levels (p = 0.001). Alongside performance status and disease stage, baseline soluble ICAM-1 could be evaluated as an additional prognostic factor in patients with small-cell lung cancer. Also, a possible role for soluble ICAM-1 may exist as a predictive marker for objective response during chemotherapy for patients with extensive disease (p = 0.001).

Intercellular adhesion molecule-1 and S-100β in sevoflurane combined with epidural anesthesia for radical resection of lung cancer

“…Therefore, we speculate that high or low concentration of ICAM-1 and S-100β before treatment can predict the survival of patients. The value of ICAM-1 as a prognostic indicator was also reported by Kotteas et al (7).…”

“…At present, chemotherapy, radiotherapy and radical resection of lung cancer are the main treatments for lung cancer in clinic (6). Radical resection of lung cancer is the first choice for patients who can be treated surgically and can accept surgical risks although the risk is relatively high (7). Anesthesia is the decisive factor for the success of the operation, sevoflurane inhalation anesthesia is the commonly used anesthesia method for thoracotomy, and combined epidural anesthesia has higher hemodynamic stability (8).…”

The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver

“…ICAM-1 is a key player in the metastatic process in a number of organs, including lung, liver and blood ( Christiansen et al, 1996 ; Kotteas et al, 2013 ). It is involved in the first stage of metastasis: adhesion of tumour cells to the endothelial cell wall (in the case of the liver, adhesion of tumour cells to the surface of LSEC).…”

Role of liver ICAM-1 in metastasis

“…Furthermore, the soluble form, sICAM-1, enhances the pro-metastatic phenotype and the pro-inflammatory and pro-tumoral signaling (45). sICAM-1 has been demonstrated to be elevated in the serum of patients with liver metastasis from lung or gastric cancer (46,47), and has been identified as a marker for metastatic stage, disease recurrence and prognosis in non-Hodgkin's lymphoma, hepatocellular carcinoma (HCC), lung cancer, and other cancer types (48)(49)(50).…”